263 related articles for article (PubMed ID: 23730503)
1. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.
Gallwitz B
Ther Adv Endocrinol Metab; 2013 Jun; 4(3):95-105. PubMed ID: 23730503
[TBL] [Abstract][Full Text] [Related]
2. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.
Gallwitz B
Diabetes Metab Syndr Obes; 2013; 6():1-9. PubMed ID: 23319869
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.
Gallwitz B
Ther Clin Risk Manag; 2015; 11():799-805. PubMed ID: 25999728
[TBL] [Abstract][Full Text] [Related]
4. Clinical Use of DPP-4 Inhibitors.
Gallwitz B
Front Endocrinol (Lausanne); 2019; 10():389. PubMed ID: 31275246
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.
Gallwitz B
Clin Med Insights Endocrinol Diabetes; 2012; 5():1-11. PubMed ID: 22879795
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Deeks ED
Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
9. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Touw DJ; Danser AHJ; Joles JA; van Raalte DH
Diabetes Care; 2020 Nov; 43(11):2889-2893. PubMed ID: 32900785
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
McKeage K
Drugs; 2014 Oct; 74(16):1927-1946. PubMed ID: 25297911
[TBL] [Abstract][Full Text] [Related]
12. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
13. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
15. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
Gillani SW; Moosvi AF
Curr Pharm Des; 2020; 26(34):4315-4322. PubMed ID: 32268860
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
18. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Danser AHJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2022 Jan; 24(1):115-124. PubMed ID: 34580975
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]